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ABSTRACT
The RAS/ERK pathway is commonly activated in
carcinomas and promotes oncogenesis by altering
transcriptional programs. However, the array of cis-
regulatory elements and trans-acting factors that
mediate these transcriptional changes is still un-
clear. Our genome-wide analysis determined that a
sequence consisting of neighboring ETS and AP-1
transcription factor binding sites is enriched near
cell migration genes activated by RAS/ERK signal-
ing in epithelial cells. In vivo screening of candi-
date ETS proteins revealed that ETS1 is specifically
required for migration of RAS/ERK activated cells.
Furthermore, both migration and transcriptional ac-
tivation through ETS/AP-1 required ERK phospho-
rylation of ETS1. Genome-wide mapping of multiple
ETS proteins demonstrated that ETS1 binds specifi-
cally to enhancer ETS/AP-1 sequences. ETS1 occu-
pancy, and its role in cell migration, was conserved
in epithelial cells derived from multiple tissues, con-
sistent with a chromatin organization common to
epithelial cell lines. Genome-wide expression anal-
ysis showed that ETS1 was required for activation of
RAS-regulated cell migration genes, but also iden-
tified a surprising role for ETS1 in the repression
of genes such as DUSP4, DUSP6 and SPRY4 that
provide negative feedback to the RAS/ERK pathway.
Consistently, ETS1 was required for robust RAS/ERK
pathway activation. Therefore, ETS1 has dual roles
in mediating epithelial-specific RAS/ERK transcrip-
tional functions.
INTRODUCTION
The RAS/RAF/MEK/ERK (RAS/ERK) pathway is acti-
vated by many growth factors and regulates cellular pro-
liferation, survival and motility. Mutations that constitu-
tively activate the RAS/ERK pathway occur in one quar-
ter of all tumors, including 95% of pancreatic cancers,
35% of lung cancers and 30% of melanomas (1). Activa-
tion of this pathway modulates the function of transcrip-
tion factors and results in altered gene expression programs
(2). Despite the clinical importance of this signaling path-
way, we lack a thorough understanding of both the cis-
regulatory sequences and trans-activating factors that or-
chestrate RAS/ERK-responsive gene expression in vivo.
Early studies focusing on the polyoma virus enhancer dis-
covered a sequencemotif that, when present in the promoter
of a reporter gene, would activate expression in response to
RAS/ERK signaling (3). This sequence consisted of neigh-
boring binding sites for ETS and AP-1 family transcription
factors (ETS/AP-1) (4). There are 28 ETS transcription fac-
tors in humans, which can be divided into 13 subfamilies of
one to three members. All ETS proteins share a conserved
DNA binding domain that mediates monomeric binding of
the ETS binding sequence, consisting of an invariant GGA
core and, most commonly, the extended sequence CCG-
GAAGT (5). AP-1 is a dimer of bZIP proteins that binds the
sequence TGA(C/G)TCA and consists of either homod-
imers from the JUN family, or heterodimers of a JUN pro-
tein bound with a FOS, ATF or MAF family member (6).
After discovery within the polyoma enhancer, ETS/AP-1
RAS-responsive elements were found in the promoters of
a handful of endogenous genes, in particular, three matrix
metalloproteases involved in cellular invasion and migra-
tion (MMP1,MMP9 and PLAU) (7–9). Despite the identi-
fication of ETS-AP1 sequences as RAS-response elements
25 years ago, the role these regulatory sequences play in
regulating specific gene expression programs is largely un-
known.
There are a number of candidates for a RAS-responsive
ETS that might function through genomic ETS/AP-1 se-
quences. When overexpressed, the ETS proteins ETS1,
ETS2 and ETV1 can activate ETS/AP-1 regulated reporter
genes (10–12), but this function has not been tested formost
ETS factors. At least nine ETS proteins can be phospho-
rylated by ERK, and in eight of these cases this modifica-
tion increases transcriptional activation (13). A deletion of
ETS2 in mice results in a phenotype similar to a deletion
of the RAS/ERK activator EGFR (14), and a deletion of
both ETS1 and ETS2 in mouse embryonic fibroblasts in-
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hibits HrasG12V transformation (15), but it is not known
what cis-regulatory sequences mediate these effects. Previ-
ous genome-wide mapping of ETS1 did not reveal occu-
pancy of ETS/AP-1 sequences (16,17) and ETS2 mapping
has not been reported due to a lack of specific antibodies.
The ETS proteins ERG, FLI1, ETV1 and ETV4 can bind
genomic ETS/AP-1 sequences when overexpressed (18,19).
However, normal adult epithelial cells and many RAS-
transformed cancer cell lines do not express any of these
ETS factors (20,21). Furthermore, when introduced into ep-
ithelial cells with an active RAS/ERK pathway, these ETS
factors do not activate an ETS/AP-1 transcriptional pro-
gram (21). Thus, although ETS/AP-1 was one of the first
described RAS-response elements, it is still unclear which
endogenous ETS protein binds ETS/AP-1 sequences across
the genome to mediate the RAS/ERK response.
Here, we report that ETS/AP-1 sequence motifs across
the human genome occur specifically at RAS/ERK-
responsive genes involved in cell migration. A comparison
of multiple ETS proteins indicated that only ETS1 was re-
quired for RAS/ERK-mediated cell migration, and ERK
phosphorylation of ETS1 was required for this function.
Chromatin immunoprecipitation coupled with next gener-
ation sequencing (ChIP-seq) identified the ETS/AP-1 se-
quence as the most enriched motif in enhancers bound
by ETS1, but not other ETS proteins. These ETS1-bound
enhancers were conserved in RAS/ERK active prostate,
lung and pancreatic cancer cells. Transcriptome analysis
revealed that ETS1 and RAS/ERK signaling regulates a
largely overlapping set of genes that neighbor ETS/AP-1
sequences. Further RNA-sequencing analysis showed that
ETS1 activates the RAS/ERK-responsive genes involved
in cell migration. However, we also discovered a surprising
group of genes that are activated by RAS/ERK signaling
and repressed by ETS1. These were largely genes that pro-
vide negative feedback to the RAS/ERK pathway. There-
fore, ETS1 mediates a positive feedback loop that activates
the RAS/ERK pathway by disrupting the negative feed-
back loop that normally attenuates RAS/ERK signaling.
Together these findings indicate that ETS1 is a major down-
stream effector of RAS/ERK signaling in epithelial cells.
MATERIALS AND METHODS
Genomic analysis of ETS/AP-1 sequences
Datasets from Caco2 cells (Ha-RAS and Ki-RAS) and
from human mammary epithelial cell (HMEC) (epithe-
lial and mesenchymal phenotypes), NCBI GEO accessions
GSE26541 and GSE12203, are used in Figure 1 and Sup-
plementary Figure S1. DNase sensitivity data is from EN-
CODE (22) with GEO accession GSM736500 Sequences
for each factor are: ETS, MGGAWRH; AP-1, TGASTCA;
CRE, TSACGTMA; SP1, KGGGVGGRRK; mutETS,
NGCGWNNN;mutAP-1, TAGSCTCA (M=AorC;W=
Aor T; R=AorG;H=A, C or T; S=GorC;K=Gor T;
V=G,A or C; N=A, C, G or T). Sequences were analyzed
in pairs with all combinations of orientation for each se-
quence and a spacing of between−1 and +20. Data in Table
1 and Supplementary Table S1 use the same sequences, but
filter with RWPE1 DNase sensitivity data from ENCODE
with UCSC accession wgEncodeEH0022553 (22).
Figure 1. ETS/AP-1 sequences predict increased activation by RAS sig-
naling. Box plots show all genes or genes with the indicated neighbor-
ing sequence, activated by expression of Ha-RASV12 or Ki-RASV12 in
Caco2 or HMEC cells. Genes are only included if the indicated sequence
is in open chromatin in the cell line where expression changed, and has the
nearest transcription start site within 25 kb. Plotted gene numbers are All:
24826, ETS/AP-1: 3849,mutETS/AP-1: 1691, ETS/CRE: 334, ETS/ETS:
1037, ETS/SP1: 2331. P-values calculated by a Welch Two Sample t-test:
***<0.0001, unmarked are >0.05.
Cell culture and viral transduction
Cell lines were cultured according to ATCC recom-
mendations as follows: EBNA293, HEK-293T, DU145
and PANC-1 were grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) [Sigma] with 10% fetal bovine
serum (FBS) [Sigma]. RWPE (RWPE-1) andRWPE-KRAS
(RWPE-2) were cultured in Keratinocyte SFM with sup-
plemental epidermal growth factor, Bovine Pituitary Ex-
tract (Invitrogen). PC3 cells were cultured in F12Kmedium
(Mediatech-Cellgro) with 10% FBS. All cell lines were
cultured in media containing 1% Penicillin/Streptomycin
100X solution (Mediatech-Cellgro).
Lentivirus for ETS factor shRNA creation was produced
by co-transfection of pLKO.1 (Addgene plasmid 8453) (23)
containing specific shRNA sequences (Supplementary Ta-
ble S4) in HEK293T cells with pMDLg/pRRE (Addgene
plasmid 12251), pRSV-Rev (Addgene plasmid 12253) and
pMD2.G (Addgene plasmid 12259) packaging plasmids
(24) as previously described (21).
Transwell migration and soft agar assays
Transwell migration assays were carried out as described
previously (18), with minor modifications. In brief, 1×105
cells were introduced to the transwell (8 M pore size;
BD Bioscience) and incubated for 12 h (PANC-1), 24 h
(DU145), 48 h (PC3) and 60 h (RWPE-1, RWPE-KRAS).
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Table 1. Roles of genes near ETS/AP-1 sequences in the genome
Dataset Most overrepresented ontologies P-value
Unfiltered Cellular component movement 1.4×10−19
Locomotion 8.7×10−19
Cell development 8.7×10−19
Response to endogenous stimulus 1.5×10−16
Cell morphogenesis 5.8×10−16




Localization of cell 2.5×10−9
The unfiltered dataset includes all ETS/AP-1 motifs (MGGAARHN(0–20)TGASTCA or MGGAWRTGASTCA) on either strand, located within 25 kb
of a RefSeq transcription start site (TSS). The RWPE1 dataset is the subset of sites within RWPE1 cell DNase sensitive regions.
The most overrepresented ontologies of the genes with the nearest TSS to sites in each category from GProfiler. Only biological process ontologies with
<2000 genes are listed.
All biological replicates are the mean of two technical repli-
cates.
Soft agar assays were carried out as described previously
(25), with minor modifications. In brief, 2×105 cells were
cultured in 0.3% agarose in DMEM on top of a lower 0.5%
agarose layer. Cells were cultured at 37◦C for four weeks
and colonies counted with TotalLab Quant software (To-
talLab).
MTT proliferation assays
Proliferation assays using 5 mg/ml MTT (Calbiochem) in
phosphate buffered saline were completed as previously
described (21) with minor changes. In brief, 800 cells of
each cell line were plated in triplicate on a 96-well flat bot-
tom culture dish and incubated at 37◦C for up to 5 days.
MTT reagent was added to each well daily and incubated
for 4 h. After incubation, media was removed and 150 l
DMSOwas added to each well. Absorbance readings at 600
nm used micro-plate reader ELx8200 (Biotek Instruments).
Each biological replicate is themean of three technical repli-
cates.
Reporter assays
A Dual Luciferase Reporter Assay System (Promega) was
used according to manufacturer’s instructions with some
modifications. Wild type and mutant ETS/AP-1 reporter
plasmids were previously described (21). Cells were plated
at ∼50% confluency in a 6-well plate (2.5×105 cells/well)
24 h before transfection. Cells were transfected with 1 g
of firefly and renilla plasmid using TransIT Prostate Trans-
fection Kit (Mirus). After 24 h, media was removed, cells
were resuspended in 250 l 1xPLB and disrupted by three
freeze/thaw cycles. Luciferase activity was measured in 20
l of cell lysate using Appliskan Multimode Microplate
reader (Thermo Scientific). Firefly values were normalized
to renilla values.
Protein immunoblotting
Total protein extract from an equal number of cells was sep-
arated on 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis gels, transferred to nitrocellulosemembrane
(Bio-Rad), blocked in 5% milk in TBS (10 mM Tris, pH8.0,
150 mMNaCl), incubated with primary and secondary an-
tibodies and visualized by ECL (Thermo Scientific) using
standard procedures. Antibodies were the same as for ChIP
plus ETV4 (Aviva), ETS2 (sc-351, Santa Cruz) and Tubulin
(Sigma).
Chromatin immunoprecipitation, sequencing and analysis
ChIP was carried out as previously described (18). In short,
cells were crosslinked using 1% v/v Formaldehyde (Fisher
Scientific) for 15 min and quenched with 2M Glycine for
5 min. Isolated cells were lysed and sonicated for 4 cy-
cles (20 s on, 40 off, 40 amplitude) [Misonix]. Nuclear
lysate was rotated with specific antibody for 4 h at 4◦C,
washed and DNA isolated by phenol/chloroform. Anti-
bodies used in ChIP were from Santa Cruz Biotechnol-
ogy: GABPA (sc-22810, lot #B2009), ETS1, (sc-350, lot
#F2811 [DU145], lot #F1312 [PANC-1]), ELF1 (sc-631,
lot #L2702), ELK4 (sc-13030, lot #G2711, JUND (sc-74,
lot #K1111). A pool of at least three biological ChIP repli-
cates was sheared to ∼150 nucleotides using a Diagenode
BioRuptor and size confirmed by gel electrophoresis. End
repair used Klenow DNA polymerase (New England Bio-
Labs), T4 DNA polymerase (New England BioLabs) and
T4 DNA ligase (New England BioLabs) before QIAquick
PCR purification (Qiagen). T4 DNA ligase (New England
BioLabs) ligated adapters. Products were size selected be-
tween 200 and 300 bp by 2% agarose gel, then purified
by Gel Extraction kit (Qiagen). Universal and indexing
adapters were from the TruSeq sample preparation kit (Il-
lumina). Libraries were multiplexed at a concentration of
20 nM and deep-sequenced with an Illumina HiSeq R©2000
instrument by manufacturer’s protocol.
Post sequencing, data was analyzed through a bioin-
formatic pipeline previously described (18). Raw .FASTQ
files were obtained from Illumina and were mapped to
the human genome (UCSC, v19). Peak calling was com-
pleted using the Useq8.4 platform (26), available: http:
//useq.sourceforge.net/. A549 ETS1 and JUND ChIP-seq
data is from Richard Meyers group, accession numbers
GSM1010829 and GSM1010723.
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Centered enriched motif analysis of ChIP-seq datasets
Centered enriched motif analysis of each ChIP-seq dataset
used the GEM algorithm, Genome wide event finding and
motif discovery (http://www.psrg.csail.mit.edu/gem/) (27).
Genomic locations were expanded 50 bp upstream and
downstream and searched by RSA-tools-peak-motifs anal-
ysis http://rsat.ulb.ac.be/ (28) to determine enriched motifs.
Motif size was 7 nucleotides and remaining parameters were
as default. Motifs were only considered and presented if
they occur in the top three of all enriched motifs.
RNA sequencing and analysis
Total RNA for three independent biological replicates
was isolated from DU145 cells transduced with lentiviral
shRNA knockdown vectors (see above), or U0126 inhibi-
tion at 50 M for 6 h (Cell Signaling) using the RNeasy
mini kit (Qiagen) according to manufacturer’s instruc-
tions. Sequencing libraries for whole transcriptome analy-
sis were generated using a modified Illumina TruSeq sam-
ple preparation protocol. Sequencing libraries for whole
transcriptome analysis were generated using a modified Il-
lumina TruSeq sample preparation protocol. Total RNA
was DNase treated with TURBO DNase (Invitrogen). The
DNase treated RNA was polyA selected with oligo(dT)
beads (Invitrogen). A Superscript III Reverse Transcrip-
tase First-Strand Synthesis (Invitrogen) system was used to
generate cDNA from the polyA selected RNA with ran-
dom hexamer primers (Invitrogen). After first strand syn-
thesis a second strand was generated using Escherichia coli
DNA ligase (NewEngland BioLabs) andE. coliDNApoly-
merase I (NewEnglandBioLabs). The double-stranded cD-
NAs were sheared to ∼150 nucleotides using a Diagenode
BioRuptor and the size was confirmed by DNA gel elec-
trophoresis. Following sonication, library preparation was
completed as described under ‘Chromatin Immunoprecipi-
tation’ methods. Deep-sequencing was performed on an Il-
luminaHiSeq R©2000 instrument by themanufacturer’s pro-
tocol. The Tuxedo Suite RNA sequencing pipeline was used
to determine differential gene expression (29) with some
modifications. Raw FASTQ files were obtained from Illu-
mina and were mapped to the human genome (UCSC re-
lease, version 19) using TopHat2 utilizing Bowtie2. Differ-
ential expression of genes and transcripts used Cuffdiff.
RESULTS
ETS/AP-1 sequences define the cis-regulatory elements of
RAS-inducible cell migration genes
Neighboring ETS/AP-1 sequences can mediate
RAS/ERK-responsive gene expression in reporter as-
says, but the role of these sequences in RAS/ERK
signaling genome-wide has not been characterized. To test
if ETS/AP-1 sequences associate with RAS-regulated genes
across the human genome, we searched for positions where
an ETS binding sequence (A/C GGAA A/G A/C/T) was
within 20 bp of an AP-1 binding sequence (TGA C/G
TCA). This spacing was chosen because it was enriched in
our previous genomic mapping of oncogenic ETS binding
sites (18). Only sequences within 25 kb of a transcription
start site (TSS) were considered, as these are the most
likely to be regulatory. We then incorporated data from two
epithelial cell lines with published datasets for both DNase
sensitivity, to predict open chromatin, and microarray
analysis to determine genes activated by RAS signaling.
These were a colorectal adenocarcinoma cell line (Caco2;
GEO accession GSE12203 (30)) and HMECs (GEO ac-
cession GSE26541). Genes with a neighboring ETS/AP-1
sequence, in open chromatin in that cell line, were signif-
icantly (P = 4.4 × 10−6) more activated by RAS than all
activated genes (Figure 1). Individual Caco2 and HMEC
datasets show the same result as the combined dataset
(Supplementary Figure S1). Multiple control sequences
were tested to verify significance, including a sequence with
a point mutation in the ETS sequence (mutETS/AP-1), and
three sequences that reflect other known ETS partnerships:
ETS/ETS, ETS/CRE and ETS/SP1. Like ETS/AP-1,
ETS/ETS and ETS/SP1 sites have also been identified
as RAS-responsive in reporter assays (31). In contrast to
the ETS/AP-1 sequence, none of the control sequences
significantly predicted highly RAS-activated genes (P >
0.05). Therefore, the ETS/AP-1 sequence can define the
cis-regulatory regions that control a RAS/ERK-regulated
gene expression program in multiple epithelial cell types.
Neighboring ETS and AP-1 binding sequences can reg-
ulate the RAS/ERK response of a handful of genes in-
volved in cellular migration and invasion. To determine
whether migration and invasion genes are the main tar-
gets of ETS/AP-1 sequences across the genome, all genes
with a neighboring ETS/AP-1 sequence (regardless of chro-
matin accessibility) were subjected to an ontology search.
This gene list was most enriched in the functional cate-
gories of cellular component movement (a category that in-
cludes both cell migration and axonal projection) and loco-
motion (Table 1). These categories were not identified us-
ing ETS/ETS, ETS/CRE or ETS/SP1 sequences (Supple-
mentary Table S1). To test if these ETS/AP-1 sequences
are accessible in epithelial cells, genomic ETS/AP-1 se-
quences were filtered with a list of DNase sensitive regions
in RWPE1 prostate epithelial cells. Genes nearest these ac-
cessible ETS/AP-1 sequences were enriched for functions
including cellular component movement, locomotion and
cell motility (Table 1). These results indicate that ETS/AP-
1 sequences can predict a RAS-responsive, cell migration
gene expression program.
ETS1, but not other ETS proteins, is required for migration
of a RAS/ERK activated cell line
In a subset of prostate cancers, aberrantly high expression
of an oncogenic ETS protein (ERG, ETV1 or ETV4) leads
to ETS/AP-1 occupancy and activation of cell migration
in backgrounds of low RAS/ERK signaling (18,21). How-
ever, normal epithelial cells, and many carcinomas, do not
express high levels of these oncogenic ETS proteins, but in-
stead can activate ETS/AP-1 reporter genes and migrate
in response to high levels of RAS/ERK signaling (21).
The ETS protein that binds ETS/AP-1 sequences across
the genome and mediates this RAS/ERK response has not
been identified. We used a shRNA knockdown approach
to test cell migration roles of five candidate ETS proteins
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in DU145, a prostate cancer cell line that does not express
high levels of oncogenic ETS proteins (21), but has an active
RAS/ERK pathway due to a chromosomal rearrangement
of KRAS (32). A lentiviral vector was used to make sta-
ble lines with shRNA-mediated depletion of ETS1, ETS2,
ELF1 or GABPA (Figure 2A). Despite very low ETV4 pro-
tein levels in this cell line (21), we were also able to de-
plete and test ETV4. In each case, lowering the level of one
ETS protein did not affect the levels of the others (Figure
2A). A transwell assay tested the migration of each knock-
down cell line in comparison to a control (luciferase) knock-
down. Loss of ETS1, and no other ETS protein, resulted in
a dramatic decrease in cell migration (Figure 2B and Sup-
plementary Figure S2A). A second shRNA targeting ETS1
had a similar effect (Supplementary Figure S2B). To verify
that this was not due to cell death, or reduced cell growth,
the proliferation rate of ETS1 knockdown cells was tested.
ETS1-depleted cells proliferated at a similar rate to con-
trol knockdown cells (Figure 2C).While depletion of ELF1,
GABPA and ETV4 had no effect on cell migration, knock-
down of ETS2, a close homolog of ETS1, actually increased
cell migration (Figure 2B), without affecting proliferation
(Supplementary Figure S2C), indicating a possible attenu-
ating function for this factor.
To test if ETS1 was functioning through ETS/AP-1 se-
quences, DU145 cells were transfected with a firefly lu-
ciferase reporter with three copies of the ETS/AP-1 se-
quence cloned upstream of a minimal promoter. Repress-
ing the RAS/ERK pathway by the MEK inhibitor U0126
decreased reporter expression about 50% (Figure 2D). Mu-
tation of the ETS binding sequences (ETSmut/AP-1) in the
reporter decreased expression to a similar extent, indicat-
ing that binding of an ETS factor is required for RAS/ERK
mediated activation. Depletion of ETS1 by shRNA resulted
in a decrease in reporter expression that approximated the
decrease by MEK inhibition or ETS site mutation (Figure
2D). This indicates that ETS1 is required for RAS/ERK
signaling to activate transcription through ETS/AP-1 se-
quences.
When overexpressed in prostate cells, oncogenic ETS
proteins can promote anchorage-independent growth and
epithelial-mesenchymal transition (EMT) in addition to cell
migration (25,33). If ETS1 is mediating RAS/ERK signal-
ing through the same cis-regulatory sequences bound by
oncogenic ETS proteins, it might have the same pheno-
types. In DU145 cells, knockdown of ETS1, but not ETV4
or ELF1 decreased anchorage independent growth (Figure
2E). ETS1 knockdown also increased E-Cadherin and de-
creased Vimentin expression consistent with a role for ETS1
in promoting EMT (Figure 2F). Interestingly, an ETS2
knockdown reduced E-Cadherin expression, again indicat-
ing an opposite or attenuating function. Therefore, in a cell
linewith an activatedRAS/ERKpathway, ETS1 is required
for transactivation through ETS/AP-1 sequences and pro-
motes cellular phenotypes associatedwith ETS/AP-1 target
genes, and ETS2 can have opposite roles.
The role of ETS1 in cell migration requires ERK phosphory-
lation
ERK can phosphorylate ETS1 at T38 and S41 residues and
this promotes transactivation by increasing affinity for the
co-activator CBP/p300 (12,34). To test the role of these
residues in the ETS1 cell migration function, a retroviral
vector system was used to stably overexpress FLAG-tagged
versions of either wild-type ETS1 or ETS1 with two ala-
nine substitutions (ETS1 T38A/S41A) in DU145 cells. As a
control, FLAG-ETS2 was also overexpressed. Each tagged
protein was expressed at similar levels, but only wild-type
ETS1 is phosphorylated at T38 (Figure 2G). Overexpres-
sion of wild-type ETS1 increased migration of DU145 cells,
but ETS1 T38A/S41A acted in a dominant negative fash-
ion and decreased cell migration (Figure 2H). ETS2 had a
similar effect as ETS1 T38A/S41A, again pointing to a role
for ETS2 in attenuating migration. None of these overex-
pression constructs altered the proliferation rate of DU145
cells (Supplementary Figure S3). The ETS/AP-1 regulated
luciferase reporter was then used to test the role of ETS1
phosphorylation in transactivation. Similar to the cell mi-
gration results, wild-type ETS1 increased reporter expres-
sion, and ETS1 T38A/S41A decreased reporter expression
(Figure 2I). Therefore the ERK phosphorylation sites in
ETS1 are required for activation of cell migration through
ETS/AP-1 cis-regulatory sequences.
If RAS/ERK signaling functions through ETS1 to acti-
vate a cell migration gene expression program, then ETS1,
despite being ubiquitously expressed, should only be nec-
essary for cell migration in cell lines with high levels of
RAS/ERK activity. To test this, we first examined PC3
prostate cancer cells, which have low ERK activation, but
migrate due to high expression of the oncogenic ETS gene
ETV4 (21,25). In PC3 cells, depletion of ETV4 decreased
cell migration, but depletion of ETS1 had no effect (Fig-
ure 3A and B), indicating no ETS1 role when RAS/ERK
activity is low. In addition, the RWPE1/2 cell system was
used to directly compare ETS1 roles in cell lines where the
only difference is in RAS/ERK activation. RWPE1 cells
are derived from normal prostate epithelia and have low
levels of ERK activation (21). Expression of Ki-RAS in
RWPE1 cells activates ERK signaling, and these cells are
called RWPE2. We have previously shown that overexpres-
sion of oncogenic ETS proteins such as ERG and ETV1
increases migration of RWPE1, but not RWPE2 cells (21).
Here, in contrast, we show that ETS1 overexpression has no
effect on RWPE1 migration (Figure 3C), but significantly
increases the migration of RWPE2 cells (Figure 3D). Con-
sistent with this observation, depleting endogenous ETS1
from RWPE2 cells results in a significant loss of cell migra-
tion (Figure 3E). In conclusion, the ability of ETS1 to trans-
activate through ETS/AP-1 sequences and drive cell migra-
tion requires RAS/ERK activation and the ERK phospho-
rylation residues T38 and S41.
ETS1 binds ETS/AP-1 sequences across the genome
These results indicate that ETS1 mediates RAS/ERK ac-
tivation through ETS/AP-1 sequences. However, previous
mapping of ETS1 binding sites in T cells by ChIP-seq did
not identify the ETS/AP-1 sequence as a common ETS1
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Figure 2. Phospho-ETS1 is required for the migration of the RAS-active prostate cancer line, DU145. (A) Immunoblot with antibodies shown (left)
of DU145 cells with shRNA mediated knockdown of five ETS factors (top). An shRNA targeting luciferase is a negative control. Tubulin is a loading
control. (B) A transwell assay measured relative cell migration of DU145 cells with indicated knockdown. Mean and SEM of ≥ 3 biological replicates
shown. P-values (*<0.05, **<0.01, ***<0.001) are calculated by two-tailed T-test. (C) An MTT assay compared proliferation of DU145 cells with ETS1
and control shRNA knockdowns. Three biological replicates shown. Proliferation rates are not significantly different (P = 0.73). (D) A reporter assay
compares relative luciferase units (firefly/renilla) from DU145 cells expressing control luciferase (luc) shRNAs or ETS1 shRNAs and treated with the
MEK inhibitor, U0126 50 M, as indicated. The firefly luciferase vector has three copies of the ETS/AP1 element (WT) 5′ to the minimal promoter or the
same vector with point mutations in each ETS binding site (MUT). Values are shown as a ratio to the first column and are the mean and SEM of three
biological replicates. P-values are as in (B). (E) Anchorage-independent growth by soft agar assay for selected ETS knockdown in DU145 cells. Number
of colonies calculated relative to luciferase shRNA. Mean and SEM of three biological replicates reported. (F) Immunoblots show levels of E-cadherin
and Vimentin in DU145 cells with the indicated shRNA knockdown. (G) Immunoblot with antibodies shown (left) for DU145 cells transduced with a
retrovirus to stably overexpress empty vector, Flag-ETS1, Flag-T38A/S41A ETS1 and Flag-ETS2. (H) A transwell assay measured relative cell migration
of DU145 cells with indicated ETS overexpression constructs as in (G). Mean and SEM of≥3 biological replicates each containing two technical replicates
are shown. P-value of ETS1 compared to T38A/S41A ETS1 by T-test. (I) Relative luciferase expression as in (D) for a 3xETS/AP-1 reporter in DU145
cells overexpressing indicated ETS construct.
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Figure 3. ETS1 only regulates cell migration in cells with an activated RAS/ERK pathway. (A) Immunoblot of PC3 cells stably expressing either luciferase,
ETS1 or ETV4 shRNAs (top) demonstrates knockdown of each ETS factor. (B) Transwell assay of PC3 cells with indicated knockdowns. Replicates and
significance as in Figure 1B. Transwell assays of RWPE1 (C) or KiRAS expressing RWPE2 (D) cells stably overexpressing retroviral ETS1. Replicates
and significance as in Figure 1B. (E) Transwell assay of RWPE2 cells transfected with stable lentiviral expression of indicated shRNA. Replicates and
significance as in Figure 1B.
binding motif (16,17). To test if this result was due to the
differences in cell type, we measured genomic occupancy of
four ETS proteins in DU145 cells by ChIP-seq (Bound re-
gions available in Supplementary Table S2). These included
three ETS proteins previously mapped in Jurkat T cells
(ETS1, GABPA and ELF1) and an additional RAS/ERK
regulated ETS protein, ELK4. As a control, two biologi-
cally independent replicates of ETS1 ChIP were sequenced,
and these showed significant convergence (Supplementary
Figure S4). In total, ETS1 bound 9994 regions andGABPA
bound 2489 regions in DU145 cells (Figure 4A). These are
similar to the number of bound regions reported for these
factors in T cells (17,35). ELF1 only occupied 247 regions
in DU145 cells, possibly due to a low expression level in
this cell type. ELK4 also bound a small number of regions
(338). Although ELK4 occupancy has not been published,
this number is very similar to the 529 bound regions re-
ported for the close ELK4 homolog, ELK1, in breast ep-
ithelia (36). ChIP/qPCR was used to confirm enrichment
of five randomly selected regions in each dataset (Supple-
mentary Figure S5). An overlap of ETS1, GABPA, ELK4
and ELF1 binding sites (Figure 4A) revealed a pattern sim-
ilar to that identified in T cells (17), with GABPA bind-
ing primarily in promoter sequences (<300 bp to TSS) that
were co-occupied by other ETS factors (redundant sites),
and the other ETS proteins having a mixture of redundant
promoter binding and specific distal enhancer binding sites
(>300 bp to TSS). The GEM algorithm (27) was used to
identify centered binding sites for each of the ETS tested.
Following GEM, windows were extended 50 bp in either
direction of the centered motif. The PeakMotifs algorithm
(28) was used to conduct an unbiased search for the most
over-represented sequence motifs in either promoter or en-
hancer binding sites. Motifs identified in promoter regions
(Supplementary Figure S6) were similar to those previously
reported in other systems (16,17), and none included AP-
1. In enhancers, GABPA and ELF1 sites were enriched for
ETS consensus sequences (Figure 3B). ELK4 sites were en-
riched for both an ETS site and a site for serum response
factor (SRF), the factor known to cooperatively bind with
ELK4 (Figure 4B). Strikingly, at ETS1 enhancer sites, the
most enriched sequence was a composite ETS/AP-1 se-
quence (CCGGAAGTGACTCA). These data indicate that
ETS1, and notGABPA, ELF1 or ELK4, binds to ETS/AP-
1 sequences in the enhancers of DU145 cells.
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Figure 4. ETS1 binds ETS/AP1 sequences in vivo. (A) Venn diagram demonstrates overlap of all ChIP-seq bound regions in DU145 cells for ETS factors
tested using Useq platform. (B) Most enriched motifs for bound enhancer regions (>300 bp from a TSS) as determined by RSAT peak-motifs algorithm
after GEM analysis. For GABPA and ELF1, only one motif was identified. (C) Overlap of ETS1 bound enhancer regions with JUND bound regions in
DU145 as determined by ChIP-seq analysis. Number in parenthesis indicates the number of expected overlaps using the assumption that any region of
open chromatin is potential binding site (determined by RWPE1 DNase-seq). (D) ETS1 and JUND occupancy is plotted by -log binary P-value near the
ETS1 gene.
To test if ETS1 co-occupies potential enhancers with AP-
1, the AP-1 subunit JUND was mapped by ChIP-seq in
DU145 cells. JUND occupancy was identified at 1145 en-
hancer regions (>300 bp to TSS). ETS1 and JUND showed
significantly overlapping binding in enhancer binding sites
with 8.5-fold more overlap than would be expected at ran-
dom (Figure 4C). However, these data also indicate that the
194 ETS1 and JUND co-occupied sites represent a subset
of the total binding sites for each protein, consistent with
our previous observations that the ETS/AP-1 motif medi-
ates a subset of both ETS and AP-1 regulatory functions
(18). ETS1 and JUND co-occupy the promoter of ETS1 it-
self (Figure 4D), consistent with an autoregulatory function
(37). In summary, consistent with ETS1 being required for
the functions of ETS/AP-1 associated genes, ETS1 binds
ETS/AP-1 sequences across the genome.
ETS/AP-1 sequences are accessible and bound by ETS1 in
multiple carcinoma cell lines
The observation that ETS1 binds to ETS/AP-1 sequences
in an epithelial-derived cell line contrasts with the previous
finding that ETS1 binds to ETS/RUNX and not ETS/AP-
1 sequences in Jurkat T cells (17). To test if chromatin ac-
cessibility explains the differences between epithelial cells
and T cells, we compared previously published ENCODE
DNase sensitivity and ChIP-seq data for Jurkat T cells with
A549 lung cancer cells, PANC1 pancreatic cancer cells and
DU145 prostate cancer cells (Table 2). The fraction of re-
gions co-occupied by ETS1 and JUND inA549 andDU145
cells or co-occupied by ETS1 and RUNX in Jurkat cells
that were in open chromatin were compared for two ep-
ithelial derived cell lines (A549 and PANC1) and Jurkat T
cells. A strikingly higher percentage of ETS1/JUND co-
occupied regions were in accessible chromatin in epithe-
lial cells than in T-cells, even when comparing epithelial
cells originating from different tissues (Table 2). In contrast
ETS1/RUNX1 co-occupied regions were much more likely
to be in open chromatin in Jurkat T cells. Therefore the dif-
ference in ETS1 binding site occupancy correlates with dif-
ferences in chromatin accessibility in these cell types.
RAS pathway activating mutations are more common
in pancreatic cancer and lung cancer than in prostate can-
cer. To test if ETS1 also plays a role in the RAS/ERK re-
sponse in these cell types, we mapped ETS1 binding sites
in PANC1 cells by ChIP-seq. Like in DU145 cells, unbi-
ased motif searching identified ETS and AP-1 sequences
at ETS1-bound enhancers in PANC1 cells (Supplemen-
tary Figure S6). A comparison of ETS1-bound regions in
PANC1, DU145 (Figure 5A) and ENCODE project data
for A549 (38) revealed very high overlap across these cell
lines, with 67% of DU145 sites, 60% of A549 sites and 89%
of PANC1 sites also occupied in another cell type. For ex-
ample, the promoter of the gene encoding Vimentin (VIM)
is shown in Figure 5B, with co-occupancy of ETS1 and
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Table 2. Cell-type specificity of open chromatin at ETS/AP-1 and ETS/RUNX bound regions
Cell line Bound factors Regions A549 DNase Jurkat DNase PANC1 DNase
A549 ETS1/JUND 4673 4570 (98%) 1767 (39%) 4121 (88%)
DU145 ETS1/JUND 383 368 (96%) 229 (60%) 323 (86%)
Jurkat ETS1/RUNX 1070 134 (13%) 690 (65%) 125 (12%)
A549, DU145 and PANC1 epithelial lines are derived from lung, prostate and pancreatic carcinomas respectively. Jurkat cells are a lymphoid line derived
from a T cell leukemia.
The number of genomic regions where both ETS1 and JUND (ETS/AP-1) or both ETS1 andRUNXbind, as indicated, based on ChIP-sequencing (17,38).
Note that the difference in the number of ETS1/JUND sites in A549 and DU145 cells is due to an ∼10-fold difference in the number of reported JUND
sites, likely due to differences in read number and peak calling in these two studies. The number of ETS1/JUND or ETS1/RUNX1 bound regions that are
in open chromatin in the indicated cell line based on global mapping of DNase sensitivity.
Figure 5. ETS1 is required for migration and demonstrates genome-wide enrichment for ETS/AP1 across multiple RAS-active cancer cell types. (A)
Overlap of ETS1-bound regions in RAS-active prostate (DU145), lung (A549) and pancreatic (PANC1) cell lines. A549 data is from ENCODE (Richard
Myers Group, GSM1010829). (B) ETS1, JUND and GABPA occupancy near the gene encoding vimentin (VIM) is plotted by -log binary P-value from
ChIP-seq data in the indicated cell lines. (C) Immunoblots compare ETS1 and tubulin (loading control) levels in PANC1 cells after treatment with shRNAs
targeting luciferase (negative control) or two independent shRNAs targeting ETS1. (D) A Boyden chamber transwell assay measures relative cell migration
of PANC1 cells expressing each lentiviral shRNA of ETS1 or luciferase shRNA control. Mean and SEM of four biological replicates shown for ETS1
shRNA #1 and two replicates for shRNA #2. P-value (*<0.05) by two-tailed T-test.
JUND in DU145, A549 and PANC1 cell lines. A poten-
tial enhancer is present at the 3′ end of VIM, with ETS1
occupancy in DU145 and A549, but not PANC1 cells. To
test the role of ETS1 in PANC1 cells, ETS1 was depleted by
shRNA (Figure 5C). Loss of ETS1 significantly decreased
the migration of PANC1 cells (Figure 5D). Together, these
data indicate that ETS1 has similar roles in regulating cell
migration through ETS/AP-1 sequences in distinct epithe-
lial derived cell lines.
ETS1 has dual roles in regulating RAS/ERK signaling
To test if ETS1 regulates expression of the same genes that
are activated by RAS/ERK signaling, DU145 cells were
treated with the MEK inhibitor U0126, and mRNA lev-
els were measured in triplicate by RNA-seq (Gene expres-
sion changes are detailed in Supplementary Table S3). Inhi-
bition of the RAS/ERK pathway decreased expression of
673 genes, and a significant fraction of these (40%), were di-
rect ETS1 target genes based on neighboring ETS1-bound
regions in the ChIP-seq dataset (Figure 6A). This repre-
sents a >3-fold increase over the random expectation (P <
0.001). Gene expression in DU145 cells depleted for ETS1
was then measured by three independent RNA-seq experi-
ments. The majority (69%) of the RAS/ERK regulated, di-
rect ETS1 target genes (as determined by ChIP-Seq, Fig-
ure 4A), changed expression when ETS1 was lost (Figure
6B). This represents a significant enrichment over the ran-
dom expectation (P< 0.001). Surprisingly, an equal number
of these direct targets were inhibited by ETS1 as were acti-
vated by ETS1. To interpret this finding, the ontologies of
the genes either activated, or inhibited, by ETS1 were iden-
tified using GoMiner (Figure 6C). As expected, the genes
activated by ETS1 were most enriched for categories as-
sociated with cell migration (Response to wounding; Pos-
itive regulation of epithelial cell migration). The genes re-
pressed by ETS1 were enriched for other categories includ-
ing ‘Negative regulation of MAPK cascade’. The genes in
this category with the highest expression changes included
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Figure 6. ETS1 regulates two positive feedback loops through two distinct mechanisms. (A) Venn diagram displaying overlap between genes downregulated
by theMEK inhibitor U0126 and genes neighboring an ETS1-bound enhancer as determined by ChIP-seq. Downregulated genes are those with significant
(P-value < 0.05) decreases after 6 h of 50 MU0126 compared to mock treated cells as measured by RNA-seq of three biological replicates. Parenthesis
indicates randomly predicted overlap. (B) The 272 genes overlapping in (A) were compared to genes with expression changes of greater than log2 = 0.2 or
−0.2 in ETS1 shRNA compared to control shRNA by RNA-seq. (C) Ontology analysis of ETS1 enhancer targets from overlaps in (B) using g:Profiler.
The top three informative, non-redundant, categories are listed along with their representative P-values. (D) Immunoblot of ETS1, ERK, pERK or tubulin
in DU145 cells treated with ETS1 shRNA or U0126, as indicated. (E) Representative immunoblot of DU145 cells expressing luciferase (control) or ETS1
shRNAs and serum starved (12 h) and treated with 50 mg/ml PMA for 5 min as indicated. (F) Quantification of immunoblots as in (E), by ImageJ. P-value
(*<0.05) by two-way T-test after three independent biological replicates. (G) Model demonstrating ETS1 regulating two distinct positive feedback loops
perpetuating RAS/ERK signaling and cell migration.
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Table 3. Genes repressed by MEK inhibition that are most activated by
ETS1 knockdown











The 10 genes with the largest increase in expression after ETS1 shRNA
treatment among genes that are direct targets of ETS1 by ChIP-seq and
are inhibited by a MEK inhibitor are shown. Column 2 is the Log (base 2)
transformed fold change in expression after ETS1 knockdown in DU145
cells. Column 3 is the Log (base 2) transformed fold change in expression
after treatment with the MEK inhibitor U0126 in DU145 cells.
DUSP4 and DUSP6 (Table 3). DUSPs are phosphatases
that directly inactivate MAPKs, including ERK, and are
known to be upregulated by RAS/ERK signaling as part
of a negative feedback loop. Our data indicate that ETS1
might disrupt this negative feedback loop by directly in-
hibiting DUSP expression. To test this, we measured ETS1
and activated ERK (pERK) levels in DU145 cells by im-
munoblotting (Figure 6D). Treatment with the MEK in-
hibitor U0126 depleted pERK and caused a decrease in
ETS1 expression consistent with ETS1 regulating its own
promoter via an ETS/AP-1 binding site (Figure 4D). How-
ever, knockdown of ETS1 resulted in only a slight decrease
in steady-state pERK levels (Figure 6D). Signaling events
that activate the RAS/ERK pathway usually result in a
peak in ERK phosphorylation followed by a decline, due
to the function of negative regulators such as the DUSPs
(39). Therefore, we hypothesized that ETS1 repression of
DUSP expression might modulate this transient activation
of ERK rather than steady-state pERK levels. DU145 cells
were serum starved overnight, and then activatedwith phor-
bol ester (PMA) for 5 min. ETS1-depleted cells showed sig-
nificantly less activation of RAS/ERK signaling than con-
trol shRNA treated cells (Figure 6E and F). Therefore, we
concluded that ETS1 functions through two positive feed-
back loops (see the model in Figure 6G). First, ETS1 ac-
tivates its own promoter in response to RAS/ERK signal-
ing. Second, ETS1 represses DUSP expression, leading to a
more robust RAS/ERK pathway activation in response to
signaling.
DISCUSSION
Here we report that the presence of an ETS/AP-1 sequence
in gene regulatory sequences can define a RAS-responsive
cell migration gene expression program, and ETS1 executes
this program. ETS1 was unique among ETS factors tested
in that it was required for migration in cell lines with an ac-
tive RAS/ERK signaling pathway. Consistent with our hy-
pothesis, ETS1 had no ability to promote cell migration in
cell lines lacking RAS/ERK activation, and the ERKphos-
phorylation sites T38 and S41 were absolutely required for
this ETS1 function. Furthermore, ETS1 bound toETS/AP-
1 sequences genome-wide and was required for activation
of target genes associated with cell migration. Surprisingly,
we also discovered a novel repressive function of ETS1 at a
subset of RAS-activated genes. This function repressed neg-
ative regulators ofRAS/ERKsignaling, allowing robust ac-
tivation of the pathway. Therefore, ETS1 represents a criti-
cal effector of RAS/ERK signaling in epithelial cells.
ETS1 is ubiquitously expressed (20) and therefore has
the potential to bind to ETS/AP-1 sites in any cell type
where this sequence is accessible. Hence, ETS1 gives the
RAS/ERK pathway the potential to activate cell migration
in any cell type with the appropriate chromatin structure.
We have previously reported that the ETS proteins that are
aberrantly expressed in prostate cancer due to chromosome
rearrangements, ERG, ETV1, ETV4 and ETV5, can also
bind to ETS/AP-1 sequences across the genome and pro-
mote prostate cell migration (18). However, these four ETS
proteins have restricted expression patterns (20). The PEA3
subfamily ETS proteins, ETV1, ETV4 and ETV5, are ex-
pressed during embryonic development, but in adults, high-
level expression is restricted to certain tissue-specific stem
cells, and their supporting cells (40,41). PEA3 proteins have
twomajor roles, promoting self-renewal of stem cells (42,43)
and promoting cellular movement, including both neuronal
and epithelial branching (44–46), with this latter role possi-
bly occurring through ETS/AP-1 cis-regulatory sequences.
ERG has similar developmental and stem cell roles (47–
49), but adult expression is restricted to the hematopoi-
etic and endothelial compartments (20). The diversity of
ETS proteins that can activate transcription upon binding
of ETS/AP-1 sequences may allow cells to alter the speci-
ficity and sensitivity of ETS/AP-1 target genes to various
signaling pathways by altering which ETS protein is bound.
For example, we have recently shown that ERG binding
of ETS/AP-1 sequences allows the PI3K/AKT pathway to
regulate these gene targets in prostate epithelial cells (21).
However, the ubiquitous presence of ETS1 provides a de-
fault setting of RAS/ERK regulation for ETS/AP-1 tar-
gets.
Despite the critical role described here for ETS1 in regu-
lating the RAS/ERK response, mice can survive without
ETS1. Homozygous disruption of ETS1 leads to an in-
crease in perinatal mortality, but surviving mice only ex-
hibit hematopoietic defects (50) that may be related to
ETS/RUNX target genes. The lack of major developmental
phenotypes might be attributed to embryonic-specific roles
of ETV1, ETV4, ETV5 and ERG at ETS/AP-1 sequences.
However, another critical playermight be the close homolog
of ETS1, ETS2. In fact, loss of ETS1 causes lethality due to
vascular rupture when combined with a hypomorphic allele
of ETS2 (51), indicating genetic redundancy in endothelial
cells. Whether ETS1 and ETS2 ever have redundant roles
in epithelial cells is not clear. ETS1 and ETS2 have been
reported to have distinct roles in some systems (52), but
the mechanisms mediating these differences are not under-
stood. In this study we find that ETS1 and ETS2 have op-
posite roles in the migration of prostate cancer cells (Figure
2B). This is consistent with previous studies indicating that
high ETS1 expression levels correlate with increased inva-
sion and poor prognosis in breast and colon cancer (53,54),
while ETS2 is tumor suppressive (55,56). Therefore, our
Nucleic Acids Research, 2014, Vol. 42, No. 19 11939
data are consistent with a specific function of ETS1 medi-
ating the RAS/ERK response in epithelial-derived tumor
cells.
ETS1 is generally considered an activator of transcrip-
tion, however, our data indicate that a similar number of di-
rect ETS1 target genes are activated as are repressed when
ETS1 is depleted. There have been a few reports of ETS1
acting to repress transcription, such as TGF- dependent
repression of collagens (57). The ability of ETS1 to switch
to a repressing function is likely through context-dependent
association with other factors. An example is the ability
of ETS1 to repress transcription of BAX when the ETS
binding sequence is directly adjacent to a GFI1 binding
sequence (58). Strikingly, three of the top four genes re-
pressed by ETS1 were negative regulators of the RAS/ERK
pathway, DUSP4, SPRY4 and DUSP6 (Table 3). Other
RAS/ERK inhibitors, including DUSP5 and SPRY2, were
also in this category. Our data indicate that increased lev-
els of these negative regulators in ETS1-depleted cells blunt
the RAS/ERK response (Figure 6E and F). Interestingly,
the third most repressed gene by ETS1 was the ETS factor
SPDEF. SPDEF is an activator of E-cadherin (59,60), and
thus could be mediating the changes in E-cadherin expres-
sion shown in Figure 1F.
Taken together, our findings indicate that ETS1 is amajor
effector of RAS/ERK signaling in epithelial cells through
both gene activation and repression. Therefore, mecha-
nisms of ETS1 function represent a new set of therapeutic
targets for the RAS/ERK signaling nexus, which is often
aberrantly activated in carcinomas.
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